Abstract | INTRODUCTION: When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed. AREAS COVERED: EXPERT OPINION: Management of COVID-19 in PLWH is no different from the general population. It should be based on careful supportive care, emphasizing lung-protective ventilation, and wise pharmacological interventions. The antiviral drug remdesivir and dexamethasone are the only pharmacological interventions with clinical benefit for COVID-19, whereas anticoagulation may prevent thrombotic complications. The experience with using these drugs in PLWH is limited, which prevents from rendering well-founded conclusions. Until more data on COVID-19 in PLWH become available, the best weapons within our reach are sound supportive care and sensible use of RDV and dexamethasone, bearing in mind the potential for drug-drug interactions of most corticosteroids and antiretroviral drugs.
|
Authors | María Del Mar Gutierrez, Isabel Mur, María Gracia Mateo, Francesc Vidal, Pere Domingo |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 22
Issue 9
Pg. 1127-1141
(Jun 2021)
ISSN: 1744-7666 [Electronic] England |
PMID | 33634724
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Retroviral Agents
- Antiviral Agents
|
Topics |
- Anti-Retroviral Agents
(therapeutic use)
- Antiviral Agents
(therapeutic use)
- COVID-19
- HIV Infections
(complications, drug therapy)
- Humans
- SARS-CoV-2
|